Journal
AUTOIMMUNITY REVIEWS
Volume 12, Issue 7, Pages 752-757Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.autrev.2012.12.006
Keywords
Antiphospholipid syndrome; Pathogenesis; Immunotherapies
Categories
Ask authors/readers for more resources
Antiphospholipid syndrome CAPS) is characterized by recurrent thrombosis and pregnancy morbidity in association with the persistent presence of circulating antiphospholipid antibodies (aPL). APS remains the most frequent cause of acquired hypercoagulability and recurrent miscarriage. Long-term anticoagulation therapy is the only treatment with proven benefit in the APS. Anticoagulation is not effective in all patients and carries a risk of bleeding. Recent improvements in the understanding of the pathogenic mechanisms have led to the identification of potential targets and future therapies for APS. In contrast to non-specific anticoagulation, the emergence of immunomodulatory drugs provides the possibility of interfering with specific pathogenic pathways. Novel therapies might be used in the future for APS. Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available